da Costa R, Passos GF, Quintao NLM, Fernandes ES, Maia J, Campos MM, Calixto JB (2020) Taxane-induced neurotoxicity: pathophysiology and therapeutic perspectives. Br J Pharmacol 177(14):3127–3146. https://doi.org/10.1111/bph.15086

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT (1971) Plant Antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93(9):2325–2327. https://doi.org/10.1021/ja00738a045

Article  CAS  PubMed  Google Scholar 

Nicolaou KC, Riemer C, Kerr MA, Rideout D, Wrasidlo W (1993) Design, synthesis and biological activity of protaxols. Nature 364(6436):464–466. https://doi.org/10.1038/364464a0

Article  CAS  PubMed  Google Scholar 

Gallego-Jara J, Lozano-Terol G, Sola-Martínez RA, Cánovas-Díaz M, de Diego Puente T (2020) A Compressive Review about Taxol(®): history and Future challenges. Molecules 25(24). https://doi.org/10.3390/molecules25245986

Muth M, Ojara FW, Kloft C, Joerger M (2021) Role of TDM-based dose adjustments for taxane anticancer drugs. Br J Clin Pharmacol 87(2):306–316. https://doi.org/10.1111/bcp.14678

Article  CAS  PubMed  Google Scholar 

Atrafi F, van Eerden RAG, van Hylckama Vlieg MAM, Oomen-de Hoop E, de Bruijn P, Lolkema MP, Moelker A, Rijcken CJ, Hanssen R, Sparreboom A, Eskens F, Mathijssen RHJ, Koolen SLW (2020) Intratumoral Comparison of Nanoparticle Entrapped Docetaxel (CPC634) with conventional docetaxel in patients with solid tumors. Clin Cancer Res 26(14):3537–3545. https://doi.org/10.1158/1078-0432.Ccr-20-0008

Article  CAS  PubMed  Google Scholar 

Paclitaxel TW (ed) (2023) UpToDate. Waltham, MA: Inc. http://www.uptodate.com. (2023) Waltham, MA: Inc.

Mosca L, Ilari A, Fazi F, Assaraf YG, Colotti G (2021) Taxanes in cancer treatment: activity, chemoresistance and its overcoming. Drug Resist Updat 54:100742. https://doi.org/10.1016/j.drup.2020.100742

Article  CAS  PubMed  Google Scholar 

Gradishar WJ (2006) Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 7(8):1041–1053. https://doi.org/10.1517/14656566.7.8.1041

Article  CAS  PubMed  Google Scholar 

Tofthagen C, McAllister RD, Visovsky C (2013) Peripheral neuropathy caused by Paclitaxel and docetaxel: an evaluation and comparison of symptoms. J Adv Pract Oncol 4(4):204–215

PubMed  PubMed Central  Google Scholar 

Molassiotis A, Cheng HL, Lopez V, Au JSK, Chan A, Bandla A, Leung KT, Li YC, Wong KH, Suen LKP, Chan CW, Yorke J, Farrell C, Sundar R (2019) Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. BMC Cancer 19(1):132. https://doi.org/10.1186/s12885-019-5302-4

Article  PubMed  PubMed Central  Google Scholar 

Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C (2008) Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26(10):1642–1649. https://doi.org/10.1200/jco.2007.11.6699

Article  CAS  PubMed  Google Scholar 

Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL, Kelley MR, Lavino A, Lustberg MB, Paice JA, Schneider BP, Lavoie Smith EM, Smith ML, Smith TJ, Wagner-Johnston N, Hershman DL (2020) Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in survivors of adult cancers: ASCO Guideline Update. J Clin Oncol 38(28):3325–3348. https://doi.org/10.1200/jco.20.01399

Article  PubMed  Google Scholar 

Speck RM, Sammel MD, Farrar JT, Hennessy S, Mao JJ, Stineman MG, DeMichele A (2013) Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer. J Oncol Pract 9(5):e234–240. https://doi.org/10.1200/jop.2012.000863

Article  PubMed  Google Scholar 

Hertz DL, Childs DS, Park SB, Faithfull S, Ke Y, Ali NT, McGlown SM, Chan A, Grech LB, Loprinzi CL, Ruddy KJ, Lustberg M (2021) Patient-centric decision framework for treatment alterations in patients with chemotherapy-induced Peripheral Neuropathy (CIPN). Cancer Treat Rev 99:102241. https://doi.org/10.1016/j.ctrv.2021.102241

Article  CAS  PubMed  Google Scholar 

Loibl S, Skacel T, Nekljudova V, Lück HJ, Schwenkglenks M, Brodowicz T, Zielinski C, von Minckwitz G (2011) Evaluating the impact of relative total dose intensity (RTDI) on patients’ short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis. BMC Cancer 11:131. https://doi.org/10.1186/1471-2407-11-131

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lyman GH, Dale DC, Crawford J (2003) Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 21(24):4524–4531. https://doi.org/10.1200/jco.2003.05.002

Article  PubMed  Google Scholar 

Gelderblom H, Verweij J, Nooter K, Sparreboom A (2001) Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37(13):1590–1598. https://doi.org/10.1016/S0959-8049(01)00171-X

Article  CAS  PubMed  Google Scholar 

Baker J, Ajani J, Scotté F, Winther D, Martin M, Aapro MS, von Minckwitz G (2009) Docetaxel-related side effects and their management. Eur J Oncol Nurs 13(1):49–59. https://doi.org/10.1016/j.ejon.2008.10.003

Article  PubMed  Google Scholar 

Wist EA, Mjaaland I, Løkkevik E, Sommer HH (2012) Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer. J Oncol 2012:862921. https://doi.org/10.1155/2012/862921

Marupudi NI, Han JE, Li KW, Renard VM, Tyler BM, Brem H (2007) Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf 6(5):609–621. https://doi.org/10.1517/14740338.6.5.609

Article  CAS  PubMed  Google Scholar 

Pusztai L (2007) Markers predicting clinical benefit in breast cancer from microtubule-targeting agents. Ann Oncol 18 Suppl 12xii15–20. https://doi.org/10.1093/annonc/mdm534

Kirino S, Tsuchiya K, Kurosaki M, Kaneko S, Inada K, Yamashita K, Osawa L, Hayakawa Y, Sekiguchi S, Okada M, Wang W, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Yasui Y, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Izumi N (2020) Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma. PLoS ONE 15(4):e0231828. https://doi.org/10.1371/journal.pone.0231828

Article  CAS  PubMed  PubMed Central  Google Scholar 

Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21(8):1431–1439. https://doi.org/10.1200/jco.2003.09.081

Article  CAS  PubMed  Google Scholar 

Del Mastro L, De Placido S, Bruzzi P, De Laurentiis M, Boni C, Cavazzini G, Durando A, Turletti A, Nisticò C, Valle E, Garrone O, Puglisi F, Montemurro F, Barni S, Ardizzoni A, Gamucci T, Colantuoni G, Giuliano M, Gravina A, Papaldo P, Bighin C, Bisagni G, Forestieri V, Cognetti F (2015) Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial. Lancet 385(9980):1863–1872. https://doi.org/10.1016/s0140-6736(14)62048-1

Article  PubMed  Google Scholar 

Increasing the dose intensity Of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials (2019). Lancet 393(10179):1440–1452. https://doi.org/10.1016/s0140-6736(18)33137-4

Cespedes Feliciano EM, Chen WY, Lee V, Albers KB, Prado CM, Alexeeff S, Xiao J, Shachar SS, Caan BJ (2020) Body composition, adherence to Anthracycline and Taxane-based chemotherapy, and Survival after nonmetastatic breast Cancer. JAMA Oncol 6(2):264–270. https://doi.org/10.1001/jamaoncol.2019.4668

Article  PubMed  Google Scholar 

Baille P, Bruno R, Schellens JH, Webster LK, Millward M, Verweij J, Montay G (1997) Optimal sampling strategies for bayesian estimation of docetaxel (Taxotere) clearance. Clin Cancer Res 3(9):1535–1538

CAS  PubMed  Google Scholar 

Engels FK, Loos WJ, van der Bol JM, de Bruijn P, Mathijssen RH, Verweij J, Mathot RA (2011) Therapeutic drug monitoring for the individualization of docetaxel dosing: a randomized pharmacokinetic study. Clin Cancer Res 17(2):353–362. https://doi.org/10.1158/1078-0432.Ccr-10-1636

Article  CAS  PubMed  Google Scholar 

Ma Y, Lin Q, Yang Y, Liang W, Salamone SJ, Li Y, Lin Y, Zhao H, Zhao Y, Fang W, Huang Y, Zhang L (2020) Clinical pharmacokinetics and drug exposure-toxicity correlation study of docetaxel based chemotherapy in Chinese head and neck cancer patients. Ann Transl Med 8(5):236. https://doi.org/10.21037/atm.2020.01.76